This examination has been performed so understand that The extent to which younger patients with intermittent claudication (IC) are offered guideline-recommended medical optimization and interventions and whether this has changed over time with the expansion of endovascular treatments are unclear. Our goal was to characterize contemporary IC treatment patterns in commercially insured non-Medicare patients.
The IBM MarketScan database, comprising >8 billion U.S. commercial insurance claims, was queried for patients newly diagnosed with IC (2007-2016). Patient demographics, medication profiles, and interventions were evaluated. Time trends were modeled using simple linear regression, and goodness of fit was assessed with coefficients of determination (R2).
Among 152,935,013 unique patients, 300,590 (.2%) were newly diagnosed with IC. Mean insurance coverage was 4.4 years. Median age was 58 years, and 56% of patients were male. Medical therapy included statins in 46% and cilostazol in 0.3% during the coverage period. Interventions were performed in 14.3%. Among these patients, 20% and 6% underwent two and three or more interventions, respectively. Median time from initial diagnosis to intervention decreased from 281 days in 2007 to 49 days in 2016.
Reference link- https://www.jvascsurg.org/article/S0741-5214(20)31433-6/fulltext
